Good start Sci Like you, I'm no expert either, but apparently...

Good start Sci
Like you, I'm no expert either, but apparently it's only the viral shedding (vs) rate we should be worrying about.
It's interesting that in the latest Paterson report, they claim Genocea only achieved a 40% reduction in vs. Your table seems to indicate a Ph.2 trial, whereas Patersons are quoting a later (?) Ph2b results of 40%.
It should also be noted that current acycolvir prescription tablets achieved 76 - 82 % reduction in their trials.
Apparently however, there is a case for using 2 successful medications together to achieve a higher overall result.
It should also be noted that if the AHZ final results are judged successful, this proves the underlying patented platform technology - which then can be put to use against other diseases and cancers.
Long term this may be where MUCH greater value lies for AHZ.